Key Highlights

  • HYEX shares slid sharply on elevated volume, a swing typical for a thinly traded OTC micro-cap and not tied to a single confirmed catalyst.
  • Second-quarter fiscal 2026 net Revenue was about $2.1 million, up roughly 113% year over year, with gross Margin above 70%.
  • Imarais Beauty shipments reached more than 4,000 retail locations, including Target, Ulta Beauty and Sprouts.
  • Management suggested annualised revenue could exceed $20 million by year-end, though cash stood near only $190,000.

A sharp intraday slide has pushed Healthy Extracts Inc back onto the radar of speculative traders, even as the small nutraceutical company reports its fastest revenue growth in years. The move in HEALTHY EXTRACTS INC (OTCQB: HYEX) shares, flagged as a sharp drop on heavy volume, lands during a period of aggressive expansion for the gummy-supplement maker. For a thinly traded micro-cap, swings of this size are common and rarely tied to a single confirmed event.

Company and Latest Development

Healthy Extracts describes itself as a leader in nutraceutical formulations and precision-dose gummy manufacturing, and trades on the OTCQB marketplace. Its portfolio spans proprietary SureDose gummy technology and consumer brands including Imarais Beauty, BergametNA and Ultimate Brain Nutrients. The company has been reshaping itself through acquisitions: it merged with Gummy USA in October 2025 and acquired the Imarais Beauty brand, founded by media personality Sommer Ray, in May 2026. That deal has helped push its products deeper into national retail.

What Is Driving Attention Around HYEX?

The move reflects a sharp single-day decline on elevated volume. Based on available sources, there is no clearly identifiable public catalyst behind that specific move; sharp swings on a small float are typical for OTC micro-caps and can occur without company-specific news. What is verifiable is a strong recent Earnings report. In its fiscal second quarter of 2026, Healthy Extracts posted record revenue and continued to push its beauty and supplement brands into major retail chains, a narrative that has drawn trading interest independent of any single-day price action.

Key Numbers and Company Position

For the second quarter of fiscal 2026, Healthy Extracts reported net revenue of about $2.1 million, up roughly 113% year over year, with Gross Profit near $1.5 million and a gross margin above 70%. The company recorded a small net loss of about $129,000, versus a modest profit a year earlier, but generated positive adjusted EBITDA of roughly $290,000. First-half revenue rose about 94% to $3.7 million. Cash stood near $190,000. Management said Imarais Beauty shipments had reached more than 4,000 retail locations, including Target, Ulta Beauty and Sprouts, and suggested annualised revenue could exceed $20 million by year-end.

What Could Come Next?

Investors may watch whether the retail rollout of Imarais Beauty and other brands translates into the revenue run-rate management has flagged. Upcoming quarterly results, additional distribution announcements, integration of acquired businesses, and any steps to strengthen the Balance Sheet could all influence sentiment. Given the company's modest cash position, any financing activity would be a key development to monitor.

Risks to Watch

Healthy Extracts remains a small, OTCQB-listed company with limited cash, raising the prospect of dilution if it needs to raise capital. Its recent slip to a net loss shows that rapid top-line growth has not yet produced consistent profitability. The consumer-supplement and beauty markets are crowded and competitive, and reliance on a handful of brands and retail partners adds concentration risk.

Retail Expansion Momentum Meets a Thin Cash Cushion

Healthy Extracts pairs standout revenue growth with the Volatility typical of a micro-cap that trades over the counter. The slide underscores how quickly sentiment can shift in low-float names, even without confirmed news. Investors following HYEX may focus on whether the company can convert its retail momentum into the roughly $20 million annualised revenue management has targeted, while keeping a close eye on cash levels and potential dilution.